Cytek Biosciences Inc
NASDAQ:CTKB
Cytek Biosciences Inc
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
Revenue: Q3 revenue was $52.3 million, up 2% year-over-year, led by strong performance in Asia Pacific and recurring revenue streams.
Regional Trends: Double-digit growth in APAC and Rest of World, with the U.S. showing double-digit growth in service revenue; EMEA declined double digits due to weak instrument sales.
Product Performance: Instrument revenue to pharma and biotech grew 12% globally, and reagents revenue rose 21% year-over-year.
Margins & Profitability: Gross margin declined to 53% from 56% a year ago, and net loss was $5.5 million, versus net income of $0.9 million last year.
Guidance: Full-year 2025 revenue guidance of $196–205 million was reaffirmed.
Growth Drivers: Recurring revenue from reagents and service, product launches like Aurora Evo, and operational improvements in reagent logistics supported growth.
Outlook: Management expects current trends to continue, with Asia Pacific strong, U.S. stabilizing, and EMEA remaining under pressure.
